Compare Stocks: ABSI, ERAS, PTCT, and GRFS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.27 +15.3%	$8.78	$2.24 ▼ $12.06	$1.59B	2.42	4.32 million shs	8.66 million shs
ERAS Erasca	$15.34 -0.1%	$17.95	$1.67 ▼ $24.28	$5.37B	0.64	5.96 million shs	7.55 million shs
GRFS Grifols	$7.40	$7.75	$6.96 ▼ $10.23	$5.04B	0.67	632,479 shs	244,639 shs
PTCT PTC Therapeutics	$68.00 +0.6%	$73.09	$57.74 ▼ $90.87	$5.68B	0.55	1.37 million shs	1.09 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+1.26%	-7.05%	-12.99%	+8.50%	+197.78%
ERAS Erasca	-5.48%	-2.17%	-15.97%	+12.36%	+798.25%
GRFS Grifols	+0.54%	-5.37%	-4.76%	0.00%	-24.72%
PTCT PTC Therapeutics	+2.96%	+0.03%	-7.26%	-14.42%	+13.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.27 +15.3%	$8.78	$2.24 ▼ $12.06	$1.59B	2.42	4.32 million shs	8.66 million shs
ERAS Erasca	$15.34 -0.1%	$17.95	$1.67 ▼ $24.28	$5.37B	0.64	5.96 million shs	7.55 million shs
GRFS Grifols	$7.40	$7.75	$6.96 ▼ $10.23	$5.04B	0.67	632,479 shs	244,639 shs
PTCT PTC Therapeutics	$68.00 +0.6%	$73.09	$57.74 ▼ $90.87	$5.68B	0.55	1.37 million shs	1.09 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+1.26%	-7.05%	-12.99%	+8.50%	+197.78%
ERAS Erasca	-5.48%	-2.17%	-15.97%	+12.36%	+798.25%
GRFS Grifols	+0.54%	-5.37%	-4.76%	0.00%	-24.72%
PTCT PTC Therapeutics	+2.96%	+0.03%	-7.26%	-14.42%	+13.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.80	Moderate Buy	$13.71	43.83% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	45.43% Upside
GRFS Grifols	1.67	Reduce	$10.00	34.68% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$98.50	45.44% Upside

Current Analyst Ratings Breakdown

Latest ABSI, ERAS, PTCT, and GRFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	PTCT PTC Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform	$98.00
9/9/2026	ABSI Absci	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$15.00
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
9/1/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	GRFS Grifols	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/14/2026	ERAS Erasca	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/13/2026	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $21.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	584.39	N/A	N/A	$1.26 per share	7.57
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
GRFS Grifols	$8.51B	0.59	$1.43 per share	5.20	$12.64 per share	0.59
PTCT PTC Therapeutics	$1.73B	3.27	$9.05 per share	7.48	($2.56) per share	-26.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	39.08	5.54	0.27	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	31.80	2.03	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)

Latest ABSI, ERAS, PTCT, and GRFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.09	1.22%	N/A	47.37%	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest ABSI, ERAS, PTCT, and GRFS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
ERAS Erasca	N/A	8.29	8.29
GRFS Grifols	1.10	2.37	0.81
PTCT PTC Therapeutics	N/A	3.39	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
ERAS Erasca	67.78%
GRFS Grifols	N/A
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
ERAS Erasca	14.20%
GRFS Grifols	0.19%
PTCT PTC Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	140	171.61 million	153.56 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable

ABSI, ERAS, PTCT, and GRFS Headlines

Recent News About These Companies

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15 at 1:00 PM | seekingalpha.com

PTC Therapeutics, Inc. $PTCT Shares Sold by Engineers Gate Manager LP

September 15 at 4:07 AM | marketbeat.com

California State Teachers Retirement System Lowers Holdings in PTC Therapeutics, Inc. $PTCT

September 15 at 3:20 AM | marketbeat.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Analysts

September 15 at 2:44 AM | americanbankingnews.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 15 at 2:13 AM | marketbeat.com

Leerink Partners Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)

September 14 at 12:05 PM | marketbeat.com

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells $678,400.00 in Stock

September 14 at 4:22 AM | americanbankingnews.com

Michael Schmertzler Sells 10,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

September 12, 2026 | insidertrades.com

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares of Stock

September 11, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.32 Million in PTC Therapeutics, Inc. $PTCT

September 11, 2026 | marketbeat.com

Hsbc Holdings PLC Reduces Holdings in PTC Therapeutics, Inc. $PTCT

September 10, 2026 | marketbeat.com

Corient Private Wealth LP Makes New Investment in PTC Therapeutics, Inc. $PTCT

September 5, 2026 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Abbott Laboratories (ABT), PTC Therapeutics (PTCT) and Ansell (OtherANSLF)

September 1, 2026 | theglobeandmail.com

Moore Capital Management LP Acquires 30,894 Shares of PTC Therapeutics, Inc. $PTCT

August 31, 2026 | marketbeat.com

Wellington Management Group LLP Raises Stake in PTC Therapeutics, Inc. $PTCT

August 31, 2026 | marketbeat.com

Empowered Funds LLC Acquires Shares of 81,271 PTC Therapeutics, Inc. $PTCT

August 31, 2026 | marketbeat.com

Legal & General Group Plc Makes New Investment in PTC Therapeutics, Inc. $PTCT

August 30, 2026 | marketbeat.com

Palo Alto Investors LP Invests $74.95 Million in PTC Therapeutics, Inc. $PTCT

August 29, 2026 | marketbeat.com

Hsbc Holdings PLC Takes $10.76 Million Position in PTC Therapeutics, Inc. $PTCT

August 29, 2026 | marketbeat.com

Michael Schmertzler Sells 12,500 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

August 28, 2026 | marketbeat.com

Jefferies Financial Group Inc. Purchases Shares of 1,357,042 PTC Therapeutics, Inc. $PTCT

August 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI, ERAS, PTCT, and GRFS Company Descriptions

Absci NASDAQ:ABSI

$9.27 +1.23 (+15.30%)

Closing price 04:00 PM Eastern

Extended Trading

$9.29 +0.02 (+0.22%)

As of 05:42 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Erasca NASDAQ:ERAS

$15.34 -0.02 (-0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$15.47 +0.13 (+0.84%)

As of 05:08 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Grifols NASDAQ:GRFS

$7.40 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.40 +0.00 (+0.07%)

As of 04:10 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

PTC Therapeutics NASDAQ:PTCT

$68.00 +0.41 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$67.99 -0.01 (-0.01%)

As of 04:11 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, ERAS, PTCT, and GRFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, ERAS, PTCT, and GRFS Earnings

Compare Dividends

Latest ABSI, ERAS, PTCT, and GRFS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, ERAS, PTCT, and GRFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI, ERAS, PTCT, and GRFS Company Descriptions

Absci NASDAQ:ABSI

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, ERAS, PTCT, and GRFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, ERAS, PTCT, and GRFS Earnings

Compare Dividends

Latest ABSI, ERAS, PTCT, and GRFS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, ERAS, PTCT, and GRFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI, ERAS, PTCT, and GRFS Company Descriptions

Absci NASDAQ:ABSI

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools